Pharvaris N.V. – Pioneering Oral Therapies for Hereditary Angioedema

Pharvaris N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with operations in the United States. The company is dedicated to developing novel, oral therapies for hereditary angioedema (HAE) and other bradykinin-mediated diseases.

Pharvaris's proprietary platform centers on deucrictibant (PHA-022121), a potent, selective, and orally bioavailable small-molecule antagonist of the bradykinin B2 receptor. The company's lead program targets HAE types I and II, which result from deficiencies or dysfunction in C1-esterase inhibitor protein. By blocking the B2 receptor directly, deucrictibant prevents the vascular permeability and fluid accumulation that cause the characteristic swelling attacks.

The company generates no current revenue, operating as a development-stage enterprise. Its primary value drivers are clinical milestones, regulatory interactions, and eventual commercialization. Pharvaris employs approximately 100 people across its Dutch and US offices, with core functions spanning R&D, clinical operations, regulatory affairs, and corporate strategy.

• Near-Term Catalysts (2025-2026): The company is expected to report topline data from its Phase 3 RAPIDe-3 trial evaluating deucrictibant for on-demand treatment of HAE attacks in the second half of 2025. Positive results would support an NDA submission in early 2026, with potential US approval and launch in late 2026 or early 2027. Additionally, the Phase 3 CHAPTER-3 prophylaxis trial is enrolling, with data anticipated in 2026.
• Medium-Term Growth Drivers (2027-2030): Following initial approvals, Pharvaris plans to expand into additional HAE subtypes, including HAE with normal C1-INH, which represents up to 20% of all HAE cases. The company is also exploring deucrictibant in other bradykinin-mediated conditions, such as acquired angioedema and drug-induced angioedema, broadening the addressable market beyond HAE.
• Commercial Expansion: Pharvaris intends to launch with a targeted US sales force of 50-75 representatives focused on the ~2,000-3,000 high-prescribing allergists/immunologists and emergency medicine specialists. European commercialization would follow through a partnership model, leveraging regional expertise to maximize market penetration across the ~20,000 diagnosed HAE patients in the EU.

Pharvaris's financial profile reflects a typical clinical-stage biotech: substantial R&D investment with no revenue until potential product launch. The company's cash position of approximately $210M at the end of 2024, combined with disciplined spending, provides runway into 2027—sufficient to reach pivotal data readouts and regulatory submissions. Operating losses are expected to widen as the company scales clinical programs and builds commercial infrastructure ahead of launch, with EPS losses peaking around -$2.71 in 2027 before narrowing as deucrictibant revenue begins to contribute materially in 2028.

The global hereditary angioedema treatment market was valued at approximately $3.5B in 2024 and is projected to grow at a CAGR of 10-12% to exceed $6B by 2030, driven by increased diagnosis rates, expanding treatment options, and growing awareness of prophylactic therapy benefits.

Pharvaris operates in a competitive landscape dominated by established players with injectable therapies:

Pharvaris's key competitive advantages include: (1) the only oral candidate targeting the B2 receptor directly, offering potential for faster onset than oral kallikrein inhibitors; (2) a dual on-demand and prophylaxis development program, allowing broader label expansion; and (3) differentiation from BioCryst's Orladeyo, the only approved oral prophylactic, which does not address acute attacks. The company's primary risk is BioCryst's potential label expansion into on-demand use, though current data suggest deucrictibant's mechanism may offer superior acute efficacy.

We value Pharvaris using a probability-weighted discounted cash flow (DCF) analysis. Our base case assumes: (1) 65% probability of US approval for on-demand indication in 2026; (2) 55% probability of prophylaxis approval by 2028; (3) peak penetration of 25% of the US HAE on-demand market and 15% of the prophylaxis market; (4) pricing of $25,000 per year for on-demand use (average 3-5 attacks annually) and $150,000 per year for prophylaxis; and (5) a 12% discount rate reflecting clinical-stage risk.

The DCF yields a risk-adjusted net present value of approximately $3.2B, implying a per-share value of $45.60. This aligns closely with the current share price of $42.09, suggesting the market has already priced in substantial clinical and regulatory success. Our comparable company analysis supports this assessment:

On an EV/peak-sales basis, Pharvaris trades at approximately 1.9x our estimated $1.5B peak sales potential, compared to BioCryst's 2.1x multiple on its $1.0B peak sales estimate. This suggests the stock is fairly valued relative to peers, with upside dependent on execution and potential label expansion beyond HAE.

• Clinical Development Risk: Deucrictibant's Phase 3 programs may fail to meet primary endpoints or demonstrate a safety profile acceptable to regulators. The on-demand trial's co-primary endpoints—time to onset of relief and time to complete resolution—are rigorous, and any statistical miss would significantly impair the investment thesis. Historical Phase 3 failure rates in HAE exceed 30%, underscoring this risk.
• Regulatory and Commercial Risk: Even with positive data, FDA or EMA may require additional trials, delay approval, or impose restrictive labeling. Post-approval, the company faces the challenge of launching without an established commercial infrastructure against entrenched competitors like Takeda and CSL Behring, who have deep payer relationships and patient support programs.
• Competitive Threat from BioCryst: BioCryst's Orladeyo, the only approved oral HAE therapy, is aggressively expanding its label and could seek an on-demand indication. Orladeyo's 2024 sales of ~$450M demonstrate growing oral therapy adoption, and BioCryst's larger commercial team and existing market presence could limit Pharvaris's penetration.
• Financing and Dilution Risk: With a projected cash runway into 2027, Pharvaris will likely require additional capital before achieving profitability. The company may need to raise $300-500M through equity offerings or partnerships, potentially diluting existing shareholders by 20-30%. Given the current $2.8B market cap, this dilution could be significant.
• Key Person and Execution Risk: Pharvaris's success depends heavily on its leadership team, particularly in regulatory strategy and commercial planning. The company's small size (~100 employees) and single-asset focus create concentration risk, with limited pipeline diversification to offset setbacks in the lead program.